MarketPulse

FDA approvals

2 articles
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Eli Lilly Edges Vertex as Superior Growth Pick Amid GLP-1 Boom

Eli Lilly ($LLY) outpaces Vertex ($VERX) as superior growth stock pick with Zepbound dominance in booming weight-loss market and stronger financials at comparable valuations.
LLYVRTXcystic fibrosispharmaceutical growth
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Lantheus Shifts Strategy, Posts $1.54B in 2025 Revenue Amid Pipeline Expansion

Lantheus posted $1.54B in 2025 revenue but faces Q4 headwinds. The company plans to refocus on PET diagnostics while exploring options for radiotherapy assets, expecting four FDA approvals in 2026.
LNTHearningsacquisitions